Hillgene, a leading biotech innovator, is headquartered in Suzhou's Wuzhong District near Taihu Lake, with a 10,000㎡ GMP-certified R&D and production base, complemented by manufacturing sites in Shenzhen and Shanghai. Expanding globally, our North Carolina (US) facility is underway. We accelerate cellular therapy development through integrated platforms: nucleic acid manufacturing, serum-free suspension culturing, closed-process automation, and advanced QC testing. These systems have empowered partners to advance CAR-T, TCR-T, and stem cell therapies from discovery to clinical delivery. Committed to accelerating timelines, Hillgene drives faster commercialization of transformative treatments, aiming to benefit patients worldwide and redefine the future of cellular therapies.
Cell Therapy Innovation Inspired
A Dedicated Solution Provider of Cell Therapy Products.
Based on the characteristics of the cell drug development process and our deep understanding of cell drugs, we have commercialized our mature cell drug quality control testing solutions and developed a series ofdetection kits that meet market demand, comprehensively addressing customer quality control needs.
• Achieved proof-of-concept for first innovative product
• Encountered critical industrialization challenges requiring strategic breakthroughs
• Established China's first serum-free suspension culturing of lentiviral vectors platform
• Filed IND applications for two therapeutic candidates (Investigational New Drug)
• Formally launched CDMO business division
• Executed and delivered first IND-stage CDMO project
• Spun off CDMO operations as independent business entity
• Commissioned 7,000+ sqm GMP facility in Suzhou (Grade B/C cleanrooms)
• Completed technology transfer for Hillgene™ platform commercialization
• Secured tens of millions in Pre-Series A financing
• Obtained China's inaugural CDMO Drug Manufacturing License for CAR-T therapies
• Hillgene Biopharma recognized as CDMO industry trailblazer
• Closed Series A financing round (CNY 10s of millions)
• Completed Series A+ funding (CNY 10s of millions)
• Accumulated cell therapy orders exceeding CNY 600 million
• Expanded global footprint with international contract wins
• Obtained EU QP Compliance Certification (EMA standards)
• Processed 300+ clinical-grade cell batches for global trials
Hillgene's social responsibilities are not explicitly detailed in the provided search results. However, based on its mission and industry context, the company focuses on advancing cellular therapy innovation to benefit patients globally, accelerating the commercialization of treatments like CAR-T, TCR-T, and stem cell therapies. While no direct CSR initiatives are mentioned, Hillgene's commitment to "writing a new chapter of life" through accessible therapies aligns with broader healthcare-related social impact goals.
400-900-1882 
info@hillgene.com 
English
